Why I Still Own Only One Stock And Why I Believe Hims & Hers Can 20x From Here

This is not financial advice. This is personal conviction turned into portfolio reality.

Six months ago, I made what most would call an irrational move.

I sold everything and went all in—on one company.

Not a broad ETF. Not a “safe” dividend stock. Not a portfolio of ten trendy tech names. Just Hims & Hers Health (HIMS).

Some called it reckless. Others quietly observed. A few asked: Why just one?

Today, I want to share not only why I still own only one stock—but why I believe Hims has the potential to become a 20-bagger from here.

Concentration is Not a Risk—It’s My Edge

Most people diversify because they don’t know what they’re doing.

I concentrate because I do.

I don’t want to get rich over 40 years. I want to make asymmetric bets today that can change my life in 5 to 10.

That’s not about ego. It’s about alignment. With how I think. With how I live. With how I want to build wealth not when I’m 70, but when I’m young enough to enjoy it.

Hims is the company I believe can deliver that kind of outcome. The kind of return that changes your net worth, your freedom, your story.

The Ingredients of a 20-Bagger

Let’s break it down. What turns a good company into a great investment? What allows one stock to go from $6 billion to $120 billion?

1. Massive TAM (Total Addressable Market) Hims is targeting healthcare, an industry that touches every human being on the planet. But not just any part of healthcare. The most emotionally driven, habitual, and highly recurring categories: hair loss, mental health, sexual wellness, skin care, and now weight loss.

2. Direct, Digital, Disruptive Hims isn’t building a traditional telehealth company. It’s building a consumer health platform, verticalized, personalized, beautifully branded, and incredibly sticky. This isn’t about accessing doctors. It’s about creating the healthcare version of Netflix: low cost, hyper-personalized, endlessly recurring.

3. Relentless Execution Read the transcripts. Watch the margins. Track the CAC and LTV. Hims isn’t just growing. It’s growing profitably. Gross margins have climbed past 80%. They’re EBITDA positive. They generate free cash flow. That kind of operational discipline is rare. And that’s where conviction lives.

Founder-Led. Culture-Aligned. And Still Under the Radar.

Andrew Dudum, the founder, is young, long-term obsessed, and unapologetically focused on customer experience.

That matters. Founder-led businesses outperform.

But more importantly: Hims doesn’t behave like a public company. It behaves like a mission-driven startup with public market discipline.

They’re scrappy. Lean. Still under the radar. And they’re building with clarity and care.

That mindset compounds. And I want to own it.

What the Market Doesn’t See

Hims is still priced like a consumer brand that sells shampoo and ED meds.

But what it actually is: a full-stack digital health infrastructure wrapped in consumer trust and retention.

They recently launched a weight loss program with GLP-1 alternatives, a non-prescription offering that builds on their model of personalized, science-backed treatments.

This is how they win:

• No reliance on expensive prescriptions

• No supply chain bottlenecks

• No need to be a pharmacy benefit manager They use trust to pull people in, then upsell through experience and retention.

That’s how you build an enduring DTC brand in healthcare.

Not by being the cheapest. But by being the most trusted.

The Optionality Is Still Mispriced

What excites me the most isn’t what Hims is doing today. It’s what this company could become tomorrow.

Right now, Wall Street sees:

• Hair loss kits

• Generic pills

• A telehealth subscription app

But what I see is:

• A health tech platform that’s training people to habitually manage their health online

• A first-party pharmacy with scale

• A data-rich loop where recurring customer behavior becomes revenue predictability

Every new vertical, mental health, weight loss, skin, sexual health, increases LTV and lowers marginal acquisition cost.

It’s not about launching new products. It’s about owning the entire health journey of the modern consumer.

Why 20x Isn’t Crazy

Let’s be concrete.

• Market cap: ~$6 billion

• Revenue run rate: over $1 billion

• Gross margins: ~80%

• Still early in penetration

Now imagine:

• 10 million subscribers

• $4 billion+ in revenue

• Sustainable 25–30% EBITDA margins

• An ecosystem that extends into diagnostics, chronic care, women’s health, AI-driven personalization

That’s not wild. That’s possible.

And a business like that? Could be worth $100–120 billion. That’s the asymmetric upside I’m betting on.

Why I Hold.

People ask if I’ll diversify.

But when you find something with this kind of potential, why would you dilute it?

Hims meets my core investment criteria:

• It addresses an essential human need

• It is developing a moat based on trust and execution

• It is underappreciated by the market

• It has excellent capital efficiency

• And I understand the business deeply

This is not just a bet.

It’s the bet.

What Would Make Me Sell?

Conviction isn’t stubbornness.

If the culture shifts.

If the execution cracks.

If the customer experience degrades.

If the capital allocation becomes reckless.

Then I’ll reassess. Fast.

But right now? Hims is hitting its stride.

And I want to stay on this ride until the real payoff arrives.

I’m Not Here to Be Average

Most investors will never get rich in stocks.

Not because they don’t have access to ideas.

But because they lack conviction when it counts.

I don’t want average.

I want life-changing.

And that starts by betting big when the odds are clearly in your favor.

One stock. One decade. One life-changing outcome.

If this resonates, subscribe to the journey. I’ll keep sharing high-conviction, research-driven, all-in investment thinking without the noise.

Because sometimes, one great idea really is enough.